Výsledky vyhledávání

Akademický článek

Salvage chemotherapy after progression on immunotherapy in recurrent/metastatic squamous cell head and neck carcinoma

Autor: Sandra Llop, Maria Plana, Sara Tous, Angelica Ferrando-Díez, Jesús Brenes, Marc Juarez, Zara Vidales, Esther Vilajosana, Isabel Linares, Lorena Arribas, Maria Duch, Marta Fulla, Aina Brunet, Alicia Lozano, Beatriz Cirauqui, Ricard Mesía, Marc Oliva

Publikováno v: Frontiers in Oncology, Vol 14 (2024)

ObjectivesAnti-PD-(L)1 agents changed the landscape of recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treatment. Previous studies showed improved response rates to salvage chemotherapy (SCT) after progression to anti-PD-(L)

Externí odkaz: https://doaj.org/article/d28979b34c654b3691bc6bfc78e1d85b

Zobrazit plný text záznamu

Akademický článek

Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti–Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 Study

Autor: Matthew G. Krebs, MD, Martin Forster, MD, PhD, Margarita Majem, MD, PhD, Julio Peguero, MD, Wade Iams, MD, Tim Clay, MD, Patricia Roxburgh, MD, PhD, Bernard Doger, MD, PhD, Pawan Bajaj, MD, Andres Barba, MD, Suvini Perera, MS, Christian Mueller, MS, Frédéric Triebel, MD, PhD

Publikováno v: JTO Clinical and Research Reports, Vol 5, Iss 11, Pp 100725- (2024)

Introduction: Eftilagimod alpha (efti), a soluble lymphocyte activation gene-3 protein, triggers antigen-presenting cell and T-cell (CD4+ and CD8+) activation and helps overcome resistance to programmed cell death protein 1 or programmed cell death-l

Externí odkaz: https://doaj.org/article/12c20e7bd714464f84bdef20677b2f93

Zobrazit plný text záznamu

Akademický článek

Circulating T cells: a promising biomarker of anti-PD-(L)1 therapy

Autor: Junlei Hou, Xuezhi Yang, Shuanglong Xie, Bo Zhu, Haoran Zha

Publikováno v: Frontiers in Immunology, Vol 15 (2024)

Anti-PD-(L)1 therapy has shown great efficacy in some patients with cancer. However, a significant proportion of patients with cancer do not respond to it. Another unmet clinical need for anti-PD-(L)1 therapy is the dynamic monitoring of treatment ef

Externí odkaz: https://doaj.org/article/cf7101fa59cb4cc29e7dd317ee2c546d

Zobrazit plný text záznamu

Akademický článek

Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC

Autor: Pedro De Marchi, Leticia Ferro Leal, Luciane Sussuchi da Silva, Rodrigo de Oliveira Cavagna, Flavio Augusto Ferreira da Silva, Vinicius Duval da Silva, Eduardo CA da Silva, Augusto O. Saito, Vladmir C. Cordeiro de Lima, Rui Manuel Reis

Publikováno v: Translational Oncology, Vol 39, Iss , Pp 101818- (2024)

Background: Immune checkpoint inhibitors (ICIs) revolutionized non-small-cell lung cancer (NSCLC) treatment. However, improving patients’ selection for this therapy is needed. Gene expression profile (GEP) is a promising biomarker tool. We assessed

Externí odkaz: https://doaj.org/article/a02a6b05d34548efa732eab520f5dd42

Zobrazit plný text záznamu

Akademický článek

A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer

Autor: Hanieh Abedian Kalkhoran, Juliëtte Zwaveling, Bert N. Storm, Sylvia A. van Laar, Johanneke EA Portielje, Henk Codrington, Dieuwke Luijten, Pepijn Brocken, Egbert F. Smit, Loes E. Visser

Publikováno v: BMC Cancer, Vol 23, Iss 1, Pp 1-12 (2023)

Abstract Background This study was designed to investigate the impact of age on the effectiveness and immune-related adverse events (irAEs) of programmed death-(ligand)1 [PD-(L)1] inhibitors in patients with non-small cell lung cancer (NSCLC) using a

Externí odkaz: https://doaj.org/article/6e2c3adabad54791a0cd2e967e1b62e7

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Mapping Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers

Autor: Esther Cabañas Morafraile, Cristina Saiz-Ladera, Cristina Nieto-Jiménez, Balázs Győrffy, Adam Nagy, Guillermo Velasco, Pedro Pérez-Segura, Alberto Ocaña

Publikováno v: Current Oncology, Vol 30, Iss 3, Pp 2569-2581 (2023)

Despite the impressive results obtained with immunotherapy in several cancer types, a significant fraction of patients remains unresponsive to these treatments. In colorectal cancer (CRC), B-RafV600 mutations have been identified in 8–15% of the pa

Externí odkaz: https://doaj.org/article/e41c2709dfde49eaa725839de2ad6b27

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

The prognostic biological markers of immunotherapy for non-small cell lung cancer: current landscape and future perspective

Autor: Shuai Liang, Hanyu Wang, Haixia Tian, Zhicheng Xu, Min Wu, Dong Hua, Chengming Li

Publikováno v: Frontiers in Immunology, Vol 14 (2023)

The emergence of immunotherapy, particularly programmed cell death 1 (PD-1) and programmed cell death ligand-1 (PD-L1) produced profound transformations for treating non-small cell lung cancer (NSCLC). Nevertheless, not all NSCLC patients can benefit

Externí odkaz: https://doaj.org/article/c00e77a15920400aa529e05af2e3fbe8

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání